Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 16, 2012

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Sickle Cell DiseaseStroke
Interventions
DRUG

Hydroxyurea

Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.

DRUG

Placebo

Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.

Trial Locations (5)

19104

Children's Hospital of Philadelphia, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

35233

University of Alabama, Birmingham

63110

St. Louis Children's Hospital, St Louis

64108

Mercy Children's Hospital, Kansas City

All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

Washington University School of Medicine

OTHER

collaborator

Vanderbilt University School of Medicine

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

RTI International

OTHER

collaborator

Columbia University

OTHER

collaborator

Children's Mercy Hospital Kansas City

OTHER

collaborator

Sinai Hospital of Baltimore

OTHER

lead

Johns Hopkins University

OTHER

NCT01389024 - Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease | Biotech Hunter | Biotech Hunter